Get the latest delivered to your inbox
Privacy Policy

Now Reading

CSL Limited (ASX:CSL) publishes its first Corporate Responsibility Report

CSL Limited (ASX:CSL) publishes its first Corporate Responsibility Report

Published 03-31-10

Issued by CSL Limited

Summary

The report details the company's approach to & performance in key areas of corporate responsibility

Report Highlights

CSL Limited has published its first Corporate Responsibility Report - Our Corporate Responsibility 2009 - available here

The report details CSL's approach to and performance in key areas of corporate responsibility. These include the Company's research into new medicines, its ongoing success in ensuring the safety and quality of its broad portfolio of therapies, providing a positive and healthy work environment for CSL employees, behaving responsibly in the global marketplace, and providing charitable support for communities in need around the world, while minimising the environmental impacts of its operations.

Highlights and statistics from some of these key areas include:

The launch of the Company's Code of Responsible Business Practice, setting out the standards of conduct expected of CSL employees and business partners
Continued investment totalling A$312 million in the research and development of protein-based medicines for the prevention and treatment of rare and serious human illnesses
A 26 percent increase in economic value distributed to the communities in which CSL operates, supported by 10 percent growth in the Company's workforce
Reduction of the Company's net water consumption by six percent at its manufacturing sites and the continued improvement of environmental intensity rates
The contribution of nearly US$10 million to patient organisations in the Company's therapeutic areas and the announcement of new support for access programs in developing countries

The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies. With major facilities in Australia, Germany, Switzerland and the US, CSL has more than 11,000 employees working in 27 countries.
require_once 'counter/results/hit.php'; //hits counter do not remove
?>

CSL Limited

CSL Limited

Join today and get the latest delivered to your inbox